Newron Pharmaceuticals Embarking on Phase II Clinical Trial for VEGF therapy in ALS

Italian clinical-stage biotechnology company Newron Pharmaceuticals has announced the initiation of a Phase II clinical trial of sNN0029 in ALS. The drug candidate is a recombinant human vascular endothelial growth factor (rhVEGF165) that is administered intracerebroventricularly, and acts by inhibiting cell death in motor neurons. In mutant SOD1 mouse models of ALS, sNN0029 increased lifespan and slowed disease progression. The drug has already been tested in humans in a Phase I/II safety study and showed preliminary evidence of efficacy. The trial will recruit 18 patients and monitor patients for 3 months.

Italian clinical-stage biotechnology company Newron Pharmaceuticals has announced the initiation of a Phase II clinical trial of sNN0029 in ALS. The drug candidate is a recombinant human vascular endothelial growth factor (rhVEGF165) that is administered intracerebroventricularly, and acts by inhibiting cell death in motor neurons. In mutant SOD1 mouse models of ALS, sNN0029 increased lifespan and slowed disease progression. The drug has already been tested in humans in a Phase I/II safety study and showed preliminary evidence of efficacy. The trial will recruit 18 patients and monitor patients for 3 months.

Click here to read more.

disease-als topic-clinical topic-randd VEGF
Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail